ArticleNature communications2024
A blueprint for broadly effective bacteriophage-antibiotic cocktails against bacterial infections.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it.
- CRISPR-Cas systems in combating antimicrobial resistance: which system to choose? A systematic review.World journal of microbiology & biotechnology · 2025Pooled it
- Phylogeny-agnostic strain-level prediction of phage-host interactions from genomes using machine learning.Nature microbiology · 2026Article
- Phage vB_KpnM_NB cocktail synergizing with amikacin in inhibiting persister cells ofApplied and environmental microbiology · 2026Article
- A consensus-based guideline for personalized bacteriophage therapy.Nature medicine · 2026Review
- Isolation and genomic characterization of bacteriophage Luminis, a lyticMicrobiology resource announcements · 2026Article
- Innovative Applications of Artificial Intelligence in Bacteriophage Research: A New Chapter in Future Medicine.Microorganisms · 2026Review
- Isolation and genomic characterization of bacteriophage Vanta, a lyticMicrobiology resource announcements · 2026Article
- Bacterial Lysis Observation Over Time Assay (BLOTS) for High-Throughput Isolation, Sequencing, and Characterization of Bacteriophages.Current protocols · 2026Article
- AI-assisted phage formulation delivered via injectable hydrogels for localized control of implant-associated infections.Bioactive materials · 2026Article
- Phage therapy: from basic biology to clinical application.Nature reviews. Microbiology · 2026Review
- Single-step monolithic chromatography efficiently purifies diverse Pseudomonas aeruginosa phages with therapeutic-grade endotoxin reduction.Npj viruses · 2026Article
- Phage as a prospective arsenal against superbugs.Molecular biology reports · 2026Review
- Pharmacology of Bacteriophage Therapy in Children: A Re-Emerging Paradigm in Antibacterial Therapy.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Bacteriophage-Based Therapeutic, Diagnostic, and Biocontrol Platforms: Engineering, Evidence, and Translational Challenges.International journal of molecular sciences · 2026Review
- Isolation, Characterization, and In Vivo Evaluation Efficacy of Lytic Bacteriophage SEP1 AgainstViruses · 2026Article
- Systematic combinatorial optimization of three-phage cocktails against multidrug-resistantMicrobiology spectrum · 2026Article
- Bacteriophage-mediated reduction of Pseudomonas aeruginosa biofilm on titanium surfaces for biomedical applications.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Artificial Intelligence in Bacteriophage Science: A Comprehensive Narrative Review of Applications, Challenges, and Translational Opportunities.Antibiotics (Basel, Switzerland) · 2026Review
- Phage Intolerance Impacts Antibiotic Susceptibility and Virulence in Staphylococcus aureus.Current microbiology · 2026Article
- Intracellular barriers and receptor masking limit success of abioRxiv : the preprint server for biology · 2026Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Bacteriophage (phage) therapy is a promising therapeutic modality for multidrug-resistant bacterial infections, but its application is mainly limited to personalized therapy due to the narrow host range of individual phages. While phage cocktails targeting all possible bacterial receptors could theoretically confer broad coverage, the extensive diversity of bacteria and the complexity of phage-phage interactions render this approach challenging. Here, using screening protocols for identifying "complementarity groups" of phages using non-redundant receptors, we generate effective, broad-range phage cocktails that prevent the emergence of bacterial resistance. We also discover characteristic interactions between phage complementarity groups and particular antibiotic classes, facilitating the prediction of phage-antibiotic as well as phage-phage interactions. Using this strategy, we create three phage-antibiotic cocktails, each demonstrating efficacy against ≥96% of 153 Pseudomonas aeruginosa clinical isolates, including biofilm cultures, and demonstrate comparable efficacy in an in vivo wound infection model. We similarly develop effective Staphylococcus aureus phage-antibiotic cocktails and demonstrate their utility of combined cocktails against polymicrobial (mixed P. aeruginosa/S. aureus) cultures, highlighting the broad applicability of this approach. These studies establish a blueprint for the development of effective, broad-spectrum phage-antibiotic cocktails, paving the way for off-the-shelf phage-based therapeutics to combat multidrug-resistant bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.